 |
|
|
|
 |
|
|
| Article 1 to 10 out of 81 concerning Genzyme Corporation
|
-
Genzyme and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics for Novel MalariaTherapies
(27 Aug 2008)
Genzyme Corp. and Medicines for Malaria Venture (MMV) announced a new collaboration with India’s Advinus Therapeutics Ltd. The collaboration seeks to develop new, improved treatments for specific patient groups most at risk for malaria.The ongoing ...
-
Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen
(08 Aug 2008)
Broad New Patent Granted
Genzyme Corp. and Isis Pharmaceuticals, Inc. announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL ...
-
Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases
(21 Jul 2008)
Genzyme Corporation and PTC Therapeutics, Inc. (PTC) announced an exclusive global collaboration to develop and commercialize PTC124, PTC's novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense ...
-
Genzyme to Build New R&D Center in Beijing
(25 Apr 2008)
Environmentally Responsible Site to Significantly Increase Company's Presence in China
Genzyme Corp. announced that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.The new ...
-
Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic
(17 Jan 2008)
Will Add to Genzyme's Personalized Medicine Testing Portfolio
Genzyme Corp. announced that it has entered into a license agreement with Moffitt Cancer Center to obtain exclusive worldwide diagnostic testing rights to the discovery of the relationship of two proteins to patient response to non-small cell lung ...
-
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
(09 Jan 2008)
Breakthrough, Potential Blockbuster Product for High Risk Cardiovascular Patients
Genzyme Corp. and Isis Pharmaceuticals, Inc. announced that they have entered a major strategic alliance in which Genzyme will develop and commercialize mipomersen, Isis' lipid-lowering treatment for high risk cardiovascular patients that utilizes ...
-
Genzyme Study of Myozyme for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
(17 Dec 2007)
Genzyme Corp. announced that its Late Onset Treatment Study (LOTS) of Myozyme® (alglucosidase alfa) met its co-primary efficacy endpoints. The study was undertaken to evaluate the safety and efficacy of Myozyme in juvenile and adult patients with ...
-
Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
(07 Dec 2007)
Genzyme Corp. announced that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar® (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are ...
-
Genzyme and Sunway to Collaborate on Gene Therapy Program in China
(29 Oct 2007)
Genzyme Corp. (NASDAQ: GENZ) and Sunway Biotech Co. Ltd. announced that they will collaborate to manufacture, develop, and commercialize the experimental gene therapy Ad2/HIF-1a in China. The product is Genzyme's most advanced gene therapy candidate ...
-
Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
(24 Oct 2007)
Genzyme Corporation and Bioenvision, Inc. announced that Bioenvision stockholders have voted to approve the acquisition of the company by Genzyme at a reconvened special shareholder meeting in New York. Bioenvision shares have now ceased trading and ...
Additional information
Genzyme Corporation
Cambridge, MA, United States of America
Company
|
|
|
|
|
|
Top
